- Home
- CHY vs PHAR Comparison
CHY vs PHAR Comparison
Compare CHY & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- PHAR
- Stock Information
- Founded
- CHY 2003
- PHAR 1988
- Country
- CHY United States
- PHAR Netherlands
- Employees
- CHY N/A
- PHAR N/A
- Industry
- CHY Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CHY Finance
- PHAR Health Care
- Exchange
- CHY Nasdaq
- PHAR Nasdaq
- Market Cap
- CHY 792.1M
- PHAR 718.1M
- IPO Year
- CHY N/A
- PHAR N/A
- Fundamental
- Price
- CHY $10.40
- PHAR $11.58
- Analyst Decision
- CHY
- PHAR Strong Buy
- Analyst Count
- CHY 0
- PHAR 3
- Target Price
- CHY N/A
- PHAR $30.00
- AVG Volume (30 Days)
- CHY 128.3K
- PHAR 3.1K
- Earning Date
- CHY 01-01-0001
- PHAR 05-08-2025
- Dividend Yield
- CHY 10.11%
- PHAR N/A
- EPS Growth
- CHY N/A
- PHAR N/A
- EPS
- CHY N/A
- PHAR N/A
- Revenue
- CHY N/A
- PHAR $320,708,000.00
- Revenue This Year
- CHY N/A
- PHAR $13.31
- Revenue Next Year
- CHY N/A
- PHAR $7.68
- P/E Ratio
- CHY N/A
- PHAR N/A
- Revenue Growth
- CHY N/A
- PHAR 24.13
- 52 Week Low
- CHY $9.97
- PHAR $6.65
- 52 Week High
- CHY $12.16
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- CHY 54.62
- PHAR 69.87
- Support Level
- CHY $10.20
- PHAR $10.02
- Resistance Level
- CHY $10.43
- PHAR $10.89
- Average True Range (ATR)
- CHY 0.12
- PHAR 0.23
- MACD
- CHY -0.02
- PHAR 0.11
- Stochastic Oscillator
- CHY 52.70
- PHAR 100.00
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.